Diamyd Medical AB: New publication highlights safety and ...
Diamyd Medical's DIAGNODE-B trial, published in the International Journal of Molecular Sciences, shows redosing Diamyd® (GAD-Alum) with vitamin D in Type 1 Diabetes patients is safe and may preserve beta-cell function, improving glycemic control and reducing insulin needs. The trial involved six participants with specific genetic traits, showing stable insulin production and immune modulation over 12 months.
Reference News
Diamyd Medical's DIAGNODE-B trial, published in the International Journal of Molecular Sciences, shows redosing Diamyd® (GAD-Alum) with vitamin D in Type 1 Diabetes patients is safe and may preserve beta-cell function, improving glycemic control and reducing insulin needs. The trial involved six participants with specific genetic traits, showing stable insulin production and immune modulation over 12 months.